Psychotropic medication during pregnancy and lactation

Archives of Gynecology and Obstetrics

Volumn 277, Issue 1, 2008, Pages 1-13

  Menon, Sharmila J ^a  

^a ROYAL GLAMORGAN HOSPITAL   (United Kingdom)

Author keywords

Lactation; Pregnancy; Psychotropic medication; Teratogenic

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; GABAPENTIN; HALOPERIDOL; HYPNOTIC AGENT; IMIPRAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VITAMIN K GROUP;

AKATHISIA; ANTICHOLINERGIC SYNDROME; BREAST FEEDING; CARDIOVASCULAR MALFORMATION; CRANIOFACIAL MALFORMATION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; FEEDING DISORDER; FETUS ELECTROCARDIOGRAPHY; FIRST TRIMESTER PREGNANCY; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFANTILE HYPOTONIA; INFORMATION RETRIEVAL; INTESTINE OBSTRUCTION; IRRITABILITY; LACTATION; LETHARGY; LOW BIRTH WEIGHT; MAJOR DEPRESSION; MEDICAL INFORMATION; MENTAL DISEASE; NEURAL TUBE DEFECT; ORTHOSTATIC HYPOTENSION; PATIENT MONITORING; PREGNANCY; PREGNANT WOMAN; PRENATAL PERIOD; PUERPERAL PSYCHOSIS; PUERPERIUM; RESPIRATION DEPRESSION; RESPIRATORY DISTRESS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SPINA BIFIDA; TERATOGENICITY; TREMOR; URINE RETENTION; WEIGHT GAIN; WITHDRAWAL SEIZURE; WITHDRAWAL SYNDROME;

ABNORMALITIES, DRUG-INDUCED; FEMALE; FETUS; HUMANS; LACTATION; MATERNAL-FETAL EXCHANGE; MENTAL DISORDERS; PATIENT CARE TEAM; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOTROPIC DRUGS;

EID: 36348946863     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-007-0433-2     Document Type: Review

References (144)

1. Miller LJ (2001) Psychiatric disorders during pregnancy. In: Stotland NL, Steward DE (eds) Psychological aspects of women's health care: the interface between psychiatry and obstetrics and gynaecology, 2nd edn. American Psychiatric Press, Washington, pp 67-93
2. Cohen LS, Rosenbaum JF (1998) Psychotropic use during pregnancy: weighing the risks. J Clin Psychiatry 59(Suppl 2):18-28
3. Levey L, Ragan K, Hower-Hartley A, Newport DJ, Stowe ZN (2004) Psychiatric disorders in pregnancy. Neurol Clin 22:863-893
4. Duffy CL (1983) Postpartum depression: identifying women at risk. Genesis 11:21
5. O'Hara MW, Neunabar DJ, Zekosi EM (1984) Prospective study of postpartum depression: prevalence, course and predictive factors. J Abnorm Psychol 93:158-171
6. McNeil TJ, Kaji L, Malquist-Larson A (1984) Women with non-organic psychosis: pregnancy's effect on mental health during pregnancy. Acta Psychiatr Scand 70:127-139
7. Neziroglu FN, Anemone MA, Yaryura-Tobias JA (1992) Onset of obsessive compulsive disorder in pregnancy. Am J Psychiatry 149:947-950
8. Williams KE, Koran L (1997) Obsessive compulsive disorder in pregnancy, the puerperium and the premenstrum. J Clin Psychiatry 58:330-334
9. Kendell RE, Chalmers JC, Platz C (1987) Epidemiology of puerperal psychosis. Br J Psychiatry 150:662-673
10. Sichel DA, Cohen LS, Dimmock JA, Rosenbaum JF (1993) Postpartum obsessive compulsive disorders: a case series. J Clin Psychiatry 54:156-159
11. Apfel RJ, Handel MH (1993) Madness and loss of motherhood: sexuality, reproduction and long-term mental illness. American Psychiatric Press, Washington
12. Sobel DE (1961) Infant mortality and malformations in children of schizophrenic women. Psychiatr Q 35:60-64
13. Oates M (2001) Death from psychiatric causes. In: Lewis G, Drife J (eds) Why mothers die 1997-1999. Confidential inquiries into maternal deaths in the United Kingdom. Royal College of Obstetricians and Gynaecologists Press, London, pp 165-187
14. Miller LJ (1997) Sexuality, reproduction and family planning in women with schizophrenia. Schizophr Bull 23:623-625
15. Dickson RA, Edwards A (1997) Clozapine and fertility. Am J Psychiatry 154:582-583
16. Kaplan B, Modai I, Stoler M, Kitai E, Valevski A, Weizman A (1995) Clozapine treatment and risk of unplanned pregnancy. J Am Board Fam Pract 8:239-241
17. Pearson KH, Nonacs R, Cohen LS (2002) Practical guidelines for the treatment of psychiatric disorders during pregnancy. In: Pearson KH, Sonawalla SB, Rosenbaum JF (eds) Womens' health and psychiatry. Lippincott, Williams and Wilkins, Philadelphia, pp 115-123
18. Orr ST, Miller CA (1995) Maternal depressive symptoms and risk of poor pregnancy outcomes: review of the literature and preliminary findings. Epidemiol Rev 17:165-171
19. Murray L (1997) The impact of postnatal depression on infant development. J Child Psychol Psychiatry 77:99-101
20. Mehta DK (2006) British National Formulary. BMA Publishing Group Ltd, London
21. Langman J (1985) Human development: normal and abnormal. In: Langman J (ed) Medical embryology. Williams and Wilkins, Baltimore, pp 123
22. Coyle I, Wayner M, Singer G (1976) Behavioural teratogenesis: a critical evaluation. Pharmacol Biochem Behav 4:191-200
23. Robertson RT, Majka JA, Peter CP, Bokelman DL (1980) Effects of prenatal exposure to chlorpromazine on postnatal development and behaviour of rats. Toxicol Appl Pharmacol 53:541-549
24. Kellogg CK (1988) Benzodiazepines: influence on the developing brain. Prog Brain Res 73:207-228
25. Kellogg C, Ison J, Miller J (1983) Prenatal diazepam exposure: effects on auditory temporal resolution in rats. Psychopharmacology 79:332-337
26. Stowe ZN, Nemeroff CB (1998) Psychopharmacology during pregnancy and lactation. In: Schatzberg AF, Nemeroff CB (eds) Textbook of psychopharmacology. American Psychiatric Press, Washington, pp 823-837
27. Elia J, Simpson JM (1990) Antidepressant medications during pregnancy and lactation; foetal teratogenic and toxic effects. In: Amsterdam JD (ed) Pharmacotherapy of depression: applications for the outpatient practitioner. Marcel Dekker, New York, pp 337-379
28. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J (1996) Pharmacological management of psychiatric illness and pregnancy: dilemmas and guidelines. Am J Psychiatry 153:592-606
29. Crombie DL, Pincent RJ, Fleming D (1972) Imipramine and pregnancy. Br Med J 2:745
30. McElhatton PR, Garbis HM, Elefant E, Vial T, Bellemin B, Mastroiacovo P, Arnon J, Rodriguez-Pinilla E, Schaefer T, Merlob P, Dal Verme S (1996) The outcome of pregnancy in 689 women exposed to therapeutic doses of anti-depressants. A collaborative study of the European Network of Teratology Information Service. Reprod Toxicol 10:285-294
31. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G (2002) Child development following exposure to tricyclic anti-depressants or fluoxetine throughout foetal life: a prospective controlled study. Am J Psychiatry 159:1889-1895
32. Ward RK, Zamorski MA (2002) Benefits and risks of psychiatric medications during pregnancy. Am Fam Physician 66:629-636
33. Cowe L, Lloyd D, Dawling S (1982) Neonatal convulsions caused by withdrawal from maternal clomipramine. Br Med J 284:1837-1838
34. Nonacs R, Cohen L (2003) Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin North Am 26:547-562
35. Ericson A, Kallen B, Wilholm B (1999) Delivery outcome after the use of anti-depressants in early pregnancy. Eur J Clin Pharmacol 55:503-508
36. Simon GE, Cunningham ML, Davies RL (2002) Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159:2055-2061
37. Nordeng H, Lindemann R, Perminov KV, Reikvam A (2001) Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediat 90:288-291
38. Goldstein DJ (1995) Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 15:417-420
39. Hendrick V, Stowe Z, Altshuler LL, Hwang S, Lee E, Haynes D (2003) Placental passage of antidepressant medications. Am J Psychiatry 160:993-996
40. Cohen L, Heller V, Bailey J, Grush L, Ablon JS, Bouffard SM (2000) Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 48:996-1000
41. Costei A, Kozer E, Ho T, Ito S, Koren G (2002) Perinatal outcome following third trimester exposure to paroxetine. Arch Paediatr Adolesc Med 156:1129-1132
42. Wogelius P, Norgaard M, Munk EM (2005) Maternal use of selective serotonin reuptake inhibitors and risk of adverse pregnancy outcome. Pharmacoepidem Drug Safety 14:S72-S73. (www.mhra.gsi.gov.uk)
43. GlaxoSmithKline Clinical Trial Register (2005) Epidemiology Study: Updated preliminary report on Bupropion in pregnancy and the occurrence of cardiovascular and major congenital malformations. (http://www.ctr.gsk.cp.uk/ Summary/paroxetine/studylist.asp)
44. Kallen B, Otterblad A, Olausson P. Anti-depressants drugs during pregnancy and infant congenital heart defect. An English translation of this information is available on the MHRA website (www.mhra.gsi.gov.uk)
45. Poulson E, Robson J (1964) Effect of phenelzine and some related compounds in pregnancy. J Endocrinol 30:205-215
46. Kohen D (2004) Psychotropic medication in pregnancy. Adv Psychiatric Treatment 10:59-66
47. Einarsen A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, Mastroiacovo P, Addis A, Matsui D, Schuler L, Einarson TR, Koren G (2001) Pregnancy outcome following gestational exposure to venlafaxine: a multicentre prospective controlled study. Am J Psychiatry 158:1728-1730
48. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, Shakir S, Einarson A (2005) Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynaecol 192:932-936
49. Van Waes A, Van De Velde E (1969) Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Psychopharmacol 9:224-237
50. Kopelman AE, McCullar FW, Heggeness L (1975) Limb malformations following maternal use of haloperidol. JAMA 231:62-64
51. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S (1977) Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight and intelligence quotient score. Am J Obstet Gynaecol 128:486-488
52. Wisner KL, Perel JM (1988) Psychopharmacological agents and electro-convulsive therapy during pregnancy and the puerperium. In: Cohen PL (ed) Psychiatric consultation in childbirth settings. Plenum, New York, pp 165-206
53. Trixler M, Tenyi T (1997) Antipsychotic use in pregnancy. What are the best treatment options? Drug Saf 16:403-410
54. Sacker A, Done DJ, Crow TJ (1996) Obstetric complications in children born to parents with schizophrenia: a meta analysis of case control studies. Psychol Med 26:279-287
55. Bennedsen BE (1998) Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors. Schizophrenia Res 33:1-26
56. Desmond MM, Rudolph AJ, Hill RM (1969) Behavioural alterations and infants born to mothers on psychoactive medication during pregnancy. In: Farrell (ed) Congenital mental retardation. University of Texas Press, Austin, pp 235-244
57. Hauser LA (1985) Pregnancy and psychotropic drugs. Hospital Commun Psychiatry 36:817-818
58. Falterman CG, Richardson C (1980) Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 97:308-310
59. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A (2005) Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 66:444-449
60. Goldstein DJ, Corbin LA, Fung MC (2000) Olanzapine exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 20:399-403
61. Gentile S (2004) Clinical utilisation of atypical antipsychotics in pregnancy and lactation. Ann Pharmacotherapy 38:1265-1271
62. Ernst C, Goldberg J (2002) The reproductive safety profile of mood stabilisers, atypical antipsychotics and broad spectrum psychotropics. J Clin Psychiatry 63(Suppl 4):42-55
63. Cohen LS, Friedman J, Jefferson JW, Johnson EM, Weiner ML (1994) A re-evaluation of risk of in utero exposure to lithium. JAMA 271:146-150
64. Nora JJ, Nora AH, Toews WH (1974) Lithium, Ebstein's anomaly and other congenital heart defects. Lancet 2:594-595
65. Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R (2002) Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 47:426-436
66. Kallen B, Tandberg A (1983) Lithium and pregnancy: a cohort study on manic depressive women. Acta Psychiatrica 68:134-139
67. Mizrahi E, Hobbs J, Goldsmith D (1979) Nephrogenic diabetes insipidus in transplacental lithium intoxication. J Paediatr 94:493-495
68. Karlsson K, Lindstedt G, Lundberg P (1975) Transplacental lithium poisoning: reversible inhibition of foetal thyroid. Lancet 1:1295
69. Llewellyn A, Stowe Z, Strader J (1998) The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 59(suppl 6):57-64
70. Pinelli J, Symington A, Cunningham K, Paes BA (2002) Case report and review of the perinatal implications of maternal lithium use. Am J Obset Gynecol 187:245-249
71. Schou M (1976) What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 54:193-197
72. Schou M (1998) Treating recurrent affective disorders during and after pregnancy. What can be taken safely? Drug Saf 18:143-152
73. Williams K, Oke S (2000) Lithium and pregnancy. Drug Inf Quartery Psychiatric Bull 24:229-231
74. Robert E, Guibaud P (1982) Maternal valproic acid and congenital neural tube defects. Lancet 2:937
75. Bjerkedal T, Czeizel A, Goujard J, Kallen B, Mastroiacova P, Nevin N, Oakley G Jr, Robert E (1982) Valproic acid and spina bifida. Lancet 2:1096
76. Jager-Roman E, Deichl A, Jakob S, Hartmann AM, Koch S, Rating D, Steldinger R, Nau H, Helge H (1986) Fetal growth, major malformations and minor anomalies in infants born to women receiving valproic acid. J Pediatr 108:997-1004
77. Briggs GG, Freeman RK, Yaffe SJ (1994) A reference guide to foetal and neonatal risk: drugs in pregnancy and lactation. Williams and Wilkins, Baltimore
78. Koch S, Jager-Roman E, Losche G, Nau H, Rating D, Helge H (1996) Anti-epileptic treatment in pregnancy: drug side-effects in neonates and neurological outcome. Acta Paediatrica 85:739-746
79. Clayton-Smith J, Donnai D (1995) Foetal valproate syndrome. J Med Genetics 32:724-727
80. Paulson G, Paulson R (1981) Teratogenic effects of anticonvulsants. Arch Neurol 38:140-143
81. Newport DJ, Fisher A, Graybeal S (2004) Psychopharmacology during pregnancy and lactation. In: Schatzberg AF, Nemeroff CB (eds) APA textbook of psychopharmacology, 3rd edn. American Psychiatric Press, Washington, pp 1109-1146
82. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ (1984) The fetal valproate syndrome. Am J Med Genet 19:473-481
83. Winter R, Donnai D, Burn J, Tucker SM (1987) Fetal valproate syndrome: is there a recognisable phenotype? J Med Genet 24:692-695
84. Mountain K, Hirsh J, Gallus A (1971) Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet 1(7641):265-268
85. Kennedy D, Koren G (1998) Valproic acid use in pregnancy: issues in treating women of reproductive age. J Psychiatry Neurosci 23:223-228
86. Ebbesen F, Joergensen A, Hoseth E, Kaad PH, Moeller M, Holsteen V, Rix M (2000) Neonatal hypoglycaemia and withdrawal symptoms after exposure in utero to valproate. Arch Dis Child Fetal Neonatal Ed 83:F124-129
87. Philbert A, Pedersen B, Dam M (1985) Concentration of valproate during pregnancy in the newborn and in breast milk. Acta Neurol Scand 72:460-463
88. Scolnik D, Nulman I Rovet J, Gladstone D, Czuchta D, Gardner HA, Gladstone R, Ashby P, Weksberg R, Einarson T (1994) Neurodevelopment of children exposed in utero to phenytoin and carbamazepine therapy. JAMA 271:767-770
89. Matalon S, Schechtman S, Goldzweig G, Ornoy A (2002) The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 16:9-17
90. Jones K, Lacro R, Johnson K, Adams J (1989) Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 320:1661-1666
91. Yonkers K, Wisner K, Stowe Z, Leibenluft E, Cohen L, Miller L, Manber R, Viguera A, Suppes T, Altshuler L (2004) Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 161:608-620
92. Dolovich L, Addis A, Vaillancourt J, Power JD, Koren G, Einarson TR (1998) Benzodiazepine use in pregnancy and major malformations or oral cleft: a meta-analysis of cohort and case control studies. BMJ 317:839-843
93. Haram K (1977) Floppy infant syndrome and maternal diazepam. Lancet 2:612-613
94. Miller L (1991) Clinical strategies for the use of psychotropic drugs during pregnancy. Psychiatr Med 9:275-298
95. Rubin PC (1981) Current concepts: beta-blockers in pregnancy. New Engl J Med 305:1323-1326
96. American Academy of Pediatrics Committee on Drugs (1994) The transfer of drugs and other chemicals into human milk. Pediatrics 93:137-150
97. Nulman I, Ito S, Koren G (2003) Anti-depressant medication and breast-feeding. In: Steiner M, Koren G (eds) Handbook of female psychopharmacology. Martin Dunitz, London, pp 103-115
98. Fergusson DM, Beautrais AL, Silva PA (1982) Breast-feeding and cognitive development in the first seven years of life. Soc Sci Med 16:1705-1708
99. Lucas A, Morley R, Cole TJ, Lister G, Leeson-Payne C (1992) Breast milk and subsequent intelligence quotient in children born pre-term. Lancet 339:261-264
100. Chaudron LH, Jefferson JW (2000) Mood stabilisers during breast-feeding: a review. J Clin Psychiatry 61:79-90
101. Llewellyn A, Stowe ZN (1998) Psychotropic medications in lactation. J Clin Psychiatry 59(suppl2):41-52
102. Mortola JF (1989) The use of psychotropic agents in pregnancy and lactation. Women's Disorders 12:69-87
103. Buist A, Norman TR, Dennerstein L (1990) Breast-feeding and the use of psychotropic medication: a review. J Affect Disord 19:197-206
104. Suri RA, Altshuler LL, Burt VK, Hendrick VC (1998) Managing psychiatric medications in the breast-feeding woman. Medscape Womens Health 3:1-10
105. Pons G, Rey E, Matheson I (1994) Excretion of psychoactive drugs into breast milk: pharmacokinetic principles and recommendations. Clin Pharmacokinet 27:270-289
106. Kohen D (2005) Psychotropic medication and breast feeding. Adv Psychiatric Treatment 11:371-379
107. Atkinson HC, Begg EJ, Darlow BA (1988) Drugs in human milk: clinical pharmacokinetic considerations. Clin Pharmacokinet 14:217-240
108. Atkinson AJ Jr, Stec GP, Lertora JJ, Ruo TI, Thenot JP (1980) Impact of active metabolites on monitoring plasma concentrations of therapeutic drugs. Ther Drug Monit 2:19-27
109. Morselli PL, Franco-Morselli R, Bossi L (1980) Clinical pharmacokinetics in newborns and infants: age related differences and therapeutic implications. Clin Pharmacokinet 5:485-527
110. Morselli PL (1976) Clinical pharmacokinetics in neonates. Clin Pharmacokinet 1:81-98
111. Wisner KL, Perel JM (1996) Nortriptyline treatment of breast-feeding women. Am J Psychiatry 153:295
112. Bennett PN (1996) Use of the monographs on drugs. In: Bennett PN (ed) Drugs and human lactation. Elsevier, Amsterdam, pp 67-74
113. Bader TF, Newman K (1980) Amitryptyline in human breast milk and nursing infants' serum. Am J Psychiatry 137:855-856
114. Stancer HC, Reed KL (1986) Desipramine and 2-hydroxydesipramine in human breast milk and the nursing infant's serum. Am J Psychiatry 143:1597-1600
115. Schimmell MS, Katz EZ, Shaag Y, Pastuszak A, Koren G (1991) Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 29:479-484
116. Wisner KL, Perel JM (1991) Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry 148:1234-1236
117. Matheson I, Panda H, Alertsen AR (1985) Respiratory depression caused by N-desmethyldoxepin in breast milk. Lancet 2:1124
118. Yoshida K, Smith B, Craggs M, Kumar RC (1998) Fluoxetine in breast milk and development outcome of breast-fed infants. Br J Psychiatry 172:175-178
119. Hale TW, Shum S, Grossberg M (2001) Fluoxetine toxicity in a breast-fed infant. Clin Paediatrics 40:681-684
120. Misri S, Kim J, Riggs KW, Kostaras X (2000) Paroxetine levels in postpartum depressed women, breast milk and infant serum. J Clin Psychiatry 61:828-832
121. Duncan D, Taylor D (1995) Which anti-depressants are safe to use in breast-feeding mothers? Psychiatric Bull 19:551-552
122. Merlob P, Stahl B, Sulkes J (2004) Paroxetine during breast feeding: infant weight gain and maternal adherence to counsel. Eur J Paediatr 163:135-139
123. Altshuler LL, Burt VK, McMullen M, Hendrick V (1995) Breast-feeding and sertraline: a 24 hour analysis. J Clin Psychiatry 56:243-245
124. Stowe ZN, Owens MJ, Landry JC, Kilts CD, Ely T, Llewellyn A, Nemeroff CB (1997) Sertraline and desmethyl sertraline in human breast milk and nursing infants. Am J Psychiatry 154:1255-1260
125. Weissman A, Levy B, Hartz A, Bentler S, Donohue M, Ellingrod VL, Wisner KL (2004) Pooled analysis of antidepressant levels in lactating mothers, breast milk and nursing infants. Am J Psychiatry 161:1066-1078
126. Jensen PN, Olesen OV, Bertelsen A, Linnet K (1997) Citalopram and desmethylcitalopram concentration in breastmilk and serum of mother and infant. Therapeutic Drug Monitoring 19:236-239
127. Spigset O, Carleborg L, Ohman R, Norstrom A (1997) Excretion of citalopram in breast milk. Br J Clin Pharmacol 44:295-298
128. Lee A, Woo J, Ito S (2004) Frequency of infant adverse effects that are associated with citalopram use during breast-feeding. Am J Obstet Gynaecol 190:218-221
129. Ilett KF, Hacket LP, Dusci LJ, Roberts MJ, Kristensen JH, Paech M, Groves A, Yapp P (1998) Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 45:459-462
130. Yoshida K, Smith B, Craggs M, Kumar R (1997) Neuroleptic drugs in breast milk: a study of pharmacokinetics and possible adverse effects in breast-fed infants. Psychol Med 28:81-91
131. Whalley LJ, Blain PG, Prime JK (1981) Haloperidol secreted in breast milk. BMJ 282:1746-1747
132. Gardiner SJ, Kristensen JH, Begg EJ, Hackett LP, Wilson DA, Ilett KF, Kohan R, Rampono J (2003) Transfer of olanzapine into breast milk, calculation of infant drug dose and effect on breast fed infants. Am J Psychiatry 160:1428-1431
133. Illett KF, Hackett LP, Kristensen JH, Vaddadi KS, Gardiner SJ, Begg EJ (2004) Transfer of risperidone and 9-hydroxyrisperidone into human milk. Ann Pharmacotherapy 38:273-276
134. Lee A, Giesbrecht E, Dunn E, Ito S (2004) Excretion of quetiapine in breast milk. Am J Psychiatry 161:1715-1716
135. Dev V, Krupp P (1995) Adverse event profile and safety of clozapine. Rev Contemporary Pharmacotherapy 6:197-208
136. American Academy of Pediatrics Committee on Drugs (2001) The transfer of drugs and other chemicals into human milk. Pediatrics 108:776-789
137. Yoshida K, Smith B, Kumar RC (1999) Psychotropic drugs in mothers' milk: a comprehensive review of assay methods, pharmacokinetics and safety of breast feeding. J Psychopharmacol 13:64-80
138. Merlob P, Mor M, Litvin A (1992) Transient hepatic dysfunction in an infant of an epileptic mother treated with carbamazepine during pregnancy and breastfeeding. Ann Pharmacotherapy 26:1563-1565
139. Nau H, Rating D, Koch S, Hauser I, Helge H (1981) Valproic acid and its metabolite: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Therapeutics 219:768-777
140. Piontek C, Baab S, Peindl KS, Wisner KL (2000) Serum valproate levels in 6 breast-feeding mother-infant pairs. J Clin Psychiatry 61:170-172
141. Sivertz K (2005) The use of psychotropic medication in pregnancy and lactation. BC Med J 47:135-138
142. Birnbaum CS, Cohen LS, Bailey JW, Grush LR, Robertson LM, Stowe ZN (1999) Serum concentration of antidepressants and benzodiazepines in nursing infants: a case series. Paediatrics 104:e11
143. Matheson I, Sande HA, Gaillot J (1990) The excretion of zopiclone into breast milk. Br J Clin Pharmacol 30:267-271
144. Bazire S (2003) Psychotropic drug directory. Fivepin Publishing, Salisbury